Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

mannkind corp - MNKD

MNKD

Close Chg Chg %
5.58 0.03 0.45%

Open Market

5.61

+0.03 (0.45%)

Volume: 130.87K

Last Updated:

Jan 16, 2026, 9:30 AM EDT

Trade Now

Company Overview: mannkind corp - MNKD

MNKD Key Data

Open

$5.59

 Day Range

5.58 - 5.61

52 Week Range

3.39 - 6.51

 Market Cap

$1.71B

Shares Outstanding

307.07M

 Public Float

298.42M

Beta

0.81

 Rev. Per Employee

N/A

P/E Ratio

59.49

 EPS

$0.10

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.49M

  

MNKD Performance

1 Week
 
 -4.62%
 
1 Month
 
 -4.45%
 
3 Months
 
 2.01%
 
1 Year
 
 -7.15%
 
5 Years
 
 77.71%
 

MNKD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About mannkind corp - MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

MNKD At a Glance

MannKind Corp.
1 Casper Street
Danbury, Connecticut 06810
Phone 1-818-661-5000 Revenue 285.50M
Industry Pharmaceuticals: Major Net Income 27.59M
Sector Health Technology 2024 Sales Growth 43.497%
Fiscal Year-end 12 / 2025 Employees 407
View SEC Filings

MNKD Valuation

P/E Current 59.809
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 66.152
Price to Sales Ratio 6.393
Price to Book Ratio N/A
Price to Cash Flow Ratio 43.34
Enterprise Value to EBITDA 22.989
Enterprise Value to Sales 6.252
Total Debt to Enterprise Value 0.088

MNKD Efficiency

Revenue/Employee 701,484.029
Income Per Employee 67,783.784
Receivables Turnover 22.298
Total Asset Turnover 0.657

MNKD Liquidity

Current Ratio 3.279
Quick Ratio 2.938
Cash Ratio 2.41

MNKD Profitability

Gross Margin 73.17
Operating Margin 24.056
Pretax Margin 10.689
Net Margin 9.663
Return on Assets 6.349
Return on Equity N/A
Return on Total Capital 35.187
Return on Invested Capital 32.551

MNKD Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 200.525
Total Debt to Total Assets 39.919
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 183.787
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Mannkind Corp - MNKD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
75.44M 99.77M 198.96M 285.50M
Sales Growth
+15.81% +32.25% +99.42% +43.50%
Cost of Goods Sold (COGS) incl D&A
38.86M 57.50M 62.77M 76.60M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.26M 6.29M 5.80M 8.97M
Depreciation
3.26M 6.29M 5.80M 8.97M
Amortization of Intangibles
- - - -
-
COGS Growth
+57.69% +47.97% +9.17% +22.03%
Gross Income
36.59M 42.27M 136.19M 208.90M
Gross Income Growth
-9.67% +15.55% +222.17% +53.39%
Gross Profit Margin
+48.49% +42.37% +68.45% +73.17%
2021 2022 2023 2024 5-year trend
SG&A Expense
89.73M 111.19M 125.60M 140.22M
Research & Development
12.31M 19.72M 31.28M 45.89M
Other SG&A
77.42M 91.47M 94.31M 94.33M
SGA Growth
+37.44% +23.92% +12.95% +11.64%
Other Operating Expense
- - - -
-
Unusual Expense
17.31M 932.00K 170.00K 21.99M
EBIT after Unusual Expense
(70.45M) (69.85M) 10.42M 46.69M
Non Operating Income/Expense
6.10M 7.22M 4.36M 21.81M
Non-Operating Interest Income
112.00K 2.51M 6.15M 12.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
16.58M 24.77M 25.16M 37.98M
Interest Expense Growth
+75.03% +49.42% +1.58% +50.95%
Gross Interest Expense
16.58M 24.77M 25.16M 37.98M
Interest Capitalized
- - - -
-
Pretax Income
(80.93M) (87.40M) (10.38M) 30.52M
Pretax Income Growth
-40.84% -8.00% +88.13% +394.09%
Pretax Margin
-107.27% -87.60% -5.22% +10.69%
Income Tax
- - 1.56M 2.93M
-
Income Tax - Current - Domestic
19.63M 9.94M (5.25M) (944.00K)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(19.63M) (9.94M) 6.81M 3.87M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(80.93M) (87.40M) (11.94M) 27.59M
Minority Interest Expense
- - - -
-
Net Income
(80.93M) (87.40M) (11.94M) 27.59M
Net Income Growth
-41.38% -8.00% +86.34% +331.09%
Net Margin Growth
-107.27% -87.60% -6.00% +9.66%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(80.93M) (87.40M) (11.94M) 27.59M
Preferred Dividends
- - - -
-
Net Income Available to Common
(80.93M) (87.40M) (11.94M) 27.59M
EPS (Basic)
-0.3247 -0.34 -0.0447 0.1005
EPS (Basic) Growth
-26.24% -4.71% +86.85% +324.83%
Basic Shares Outstanding
249.24M 257.09M 267.01M 274.42M
EPS (Diluted)
-0.3247 -0.34 -0.0447 0.0972
EPS (Diluted) Growth
-26.24% -4.71% +86.85% +317.45%
Diluted Shares Outstanding
249.24M 257.09M 267.01M 283.84M
EBITDA
(49.89M) (62.63M) 16.39M 77.65M
EBITDA Growth
-128.75% -25.55% +126.18% +373.61%
EBITDA Margin
-66.12% -62.78% +8.24% +27.20%

Snapshot

Average Recommendation BUY Average Target Price 9.389
Number of Ratings 9 Current Quarters Estimate 0.01
FY Report Date 03 / 2026 Current Year's Estimate 0.095
Last Quarter’s Earnings 0.02 Median PE on CY Estimate N/A
Year Ago Earnings 0.171 Next Fiscal Year Estimate 0.237
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 9 9
Mean Estimate 0.01 0.02 0.09 0.24
High Estimates 0.04 0.05 0.18 0.61
Low Estimate -0.05 -0.01 -0.02 0.07
Coefficient of Variance 519.62 150.00 75.55 64.46

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 9
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Mannkind Corp - MNKD

Date Name Shares Transaction Value
May 21, 2025 Stuart A. Tross Chief People & Workpl Officer 1,090,427 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.37 per share 4,765,165.99
May 21, 2025 David B. Thomson EVP Genl Counsel & Secretary 881,891 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.37 per share 3,853,863.67
May 21, 2025 David B. Thomson EVP Genl Counsel & Secretary 879,546 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.41 per share 3,878,797.86
May 21, 2025 Michael E. Castagna Chief Executive Officer; Director 2,612,934 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.37 per share 11,418,521.58
May 21, 2025 Steven B. Binder Director 1,001,421 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.37 per share 4,376,209.77
May 21, 2025 Steven B. Binder Director 989,343 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.4 per share 4,353,109.20

Mannkind Corp in the News